Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Hadaczek, Piotr ^a   Beyer, Janine ^a   Kells, Adrian ^a   Narrow, Wade ^b   Bowers, William ^b   Federoff, Howard J ^c   Forsayeth, John ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AAV2 VECTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; RAPAMYCIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DELIVERY SYSTEM; DRUG SCREENING; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; KINETICS; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NEUROMODULATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; REGULATORY MECHANISM; SYSTEM ANALYSIS; TRANSGENE; TREATMENT DURATION; ADENO ASSOCIATED VIRUS; ANIMAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; EVALUATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; NEOSTRIATUM; SPRAGUE DAWLEY RAT; TIME;

RATTUS;

ANIMALS; DEPENDOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; MALE; NEOSTRIATUM; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; SPECIMEN HANDLING; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 81455125493     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027728     Document Type: Article

References (42)

1. Airaksinen MS, Saarma M, (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394.
2. Airaksinen MS, Titievsky A, Saarma M, (1999) GDNF family neurotrophic factor signaling: four masters, one servant? Mol Cell Neurosci 13: 313-325.
3. Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, et al. (1998) Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18: 4929-4937.
4. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F, (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons [see comments]. Science 260: 1130-1132.
5. Oiwa Y, Yoshimura R, Nakai K, Itakura T, (2002) Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Res 947: 271-283.
6. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gomez-Diaz R, et al. (2008) Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11: 755-761.
7. Rosenblad C, Kirik D, Bjorklund A, (1999) Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. Neuroreport 10: 1783-1787.
8. Kells AP, Eberling J, Su X, Pivirotto P, Bringas J, et al. (2010) Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 30: 9567-9577.
9. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, et al. (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60: 69-73.
10. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, et al. (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46: 419-424.
11. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, et al. (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57: 298-302.
12. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466.
13. Chebrolu H, Slevin JT, Gash DA, Gerhardt GA, Young B, et al. (2006) MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF). Exp Neurol 198: 450-456.
14. Barker RA, (2006) Continuing trials of GDNF in Parkinson's disease. Lancet Neurol 5: 285-286.
15. Penn RD, Dalvi A, Slevin J, Young B, Gash D, et al. (2006) GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 5: 202-203.
16. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Young AB, (2006) Reply: GDNF poses troubling questions for doctors, drug maker. Ann Neurol 59: 989-990.
17. Hovland DN Jr, Boyd RB, Butt MT, Engelhardt JA, Moxness MS, et al. (2007) Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 35: 1013-1029.
18. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290: 767-773.
19. Eberling JL, Kells AP, Pivirotto P, Beyer J, Bringas J, et al. (2009) Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 20: 511-518.
20. Pollock R, Clackson T, (2002) Dimerizer-regulated gene expression. Curr Opin Biotechnol 13: 459-467.
21. Hadaczek P, Johnston L, Forsayeth J, Bankiewicz KS, (2010) Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain. Neuropharmacology 58: 1114-1121.
22. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, et al. (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23: 5294-5304.
23. Johnston LC, Eberling J, Pivirotto P, Hadaczek P, Federoff HJ, et al. (2009) Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 20: 497-510.
24. Milligan ED, Sloane EM, Langer SJ, Cruz PE, Chacur M, et al. (2005) Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain 1: 9.
25. Urabe M, Ding C, Kotin RM, (2002) Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 13: 1935-1943.
26. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, et al. (2008) Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 173: 1768-1782.
27. Smith RH, Levy JR, Kotin RM, (2009) A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 17: 1888-1896.
28. Yin D, Forsayeth J, Bankiewicz KS, (2010) Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods 187: 46-51.
29. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, et al. (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23: 357-361.
30. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, et al. (2007) Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 13: 7401-7406.
31. Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, et al. (2005) Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25: 769-777.
32. Auricchio A, Rivera VM, Clackson T, O'Connor EE, Maguire AM, et al. (2002) Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther 6: 238-242.
33. Fan DS, Ogawa M, Fujimoto KI, Ikeguchi K, Ogasawara Y, et al. (1998) Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum Gene Ther 9: 2527-2535.
34. Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, et al. (2000) Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 11: 1509-1519.
35. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, et al. (1999) Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 73: 9468-9477.
36. Wang S, Petravicz J, Breakefield XO, (2003) Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Mol Ther 7: 790-800.
37. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, et al. (2005) Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105: 1424-1430.
38. Pollock R, Issner R, Zoller K, Natesan S, Rivera VM, et al. (2000) Delivery of a stringent dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad Sci U S A 97: 13221-13226.
39. Su X, Kells AP, Aguilar Salegio EA, Richardson RM, Hadaczek P, et al. (2010) Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther 18: 1490-1495.
40. Salegio EA, Kells AP, Richardson RM, Hadaczek P, Forsayeth J, et al. (2010) Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum Gene Ther 21: 1093-1103.
41. Sanftner LM, Rivera VM, Suzuki BM, Feng L, Berk L, et al. (2006) Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. Mol Ther 13: 167-174.
42. Chyung YH, Peng PD, Kay MA, (2003) System for simultaneous tissue-specific and disease-specific regulation of therapeutic gene expression. Hum Gene Ther 14: 1255-1264.